Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The service requirements for the direct supply and administration of Lecanemab (Leqembi) in a patient's home, via a homecare delivery service. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoE ε 4) heterozygotes or non-carriers. The service is being offered by UCLH private Healthcare and will be for private patients only. The requirement is for a private homecare provider situated in the UK to provide this service.
Additional information:
To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.
Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:
Phone: 0800 9956035
E-mail: …@atamis.co.uk
No supplier information available.